MedTrace Logo

Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy

NCT03267381 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2023-12-14

No results posted yet for this study

Summary

To study if a targeted gene expression profile of RNA, similar to the NETest, can be isolated from the peripheral blood of patients with melanoma, to identify active disease, provide an assessment of treatment responses, or predict risk of relapse, in conjunction with standard clinical assessment and imaging.

Conditions

Interventions

OTHER

Blood draw (before surgery)

Blood will be drawn before surgery

OTHER

Blood draw (every 3 months)

Blood will be drawn every 3 months

OTHER

Blood draw (at diagnosis)

Blood will be drawn at time of diagnosis

Sponsors & Collaborators

  • Wren Laboratories LLC

    collaborator INDUSTRY

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Rondi Kauffmann, MD · vanderbilt Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-03
Primary Completion
2023-09-27
Completion
2023-09-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03267381 on ClinicalTrials.gov